Dr. David Bergin

Dave graduated with a M.Sc. and Ph.D. in Neuroscience from the University of Otago, New Zealand, during which he examined the effects of agmatine treatment on behavioural and neurochemical biomarkers in models of Alzheimer’s disease. He remained at the University of Otago for his first postdoctoral research position in the group led by Unit collaborator Prof. John Reynolds, with whom Dave established a novel model of Parkinsonism to help advance a multidisciplinary drug delivery system. Following this success, Dave moved in 2017 to the University of Veterinary Medicine Hannover, Germany, to join the EU consortium EPITARGET, where his research was focused on the use of combination therapy with clinically-approved drugs for the prevention of post-insult epileptogenesis.

Dave worked in the Unit as part of the Magill Group from October 2018 to January 2022. His research was centred on the development and delivery of novel in vivo platforms for drug discovery in Parkinson’s disease, as part of the Unit’s translational research venture with partners at the University of Oxford and in industry. Dave continues to collaborate with the Magill Group.